AKT1 and hepatocellular carcinoma: The following cell lines were used to evaluate these combinations: MDA-MB-453 and HCC-1954, both of which harbor an oncogenic PIK3CA mutation; and MDA-MB-231 and SK-BR3, which harbor molecular alterations linked to increased AKT activity and PI3K-inhibition sensitivity [48].